High-potency botulinum toxin formulations
US8679486B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Apr 5, 2010 |
| Grant date | Mar 25, 2014 |
| Priority date | — |
| Expiry date | Apr 5, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P29/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides improved formulations of botulinum toxin that increase delivery of the botulinum toxin to neural and associated tissues and exhibit a higher specific neurotoxicity and higher potency (in LD50 Units) than available formulations of botulinum toxins. These improved formulations enable physicians to treat a wide variety of pathological conditions with a lower toxin load that reduces the risk of inducing an immune response against the toxin and its associated proteins that may ultimately lead to the development of toxin resistance. These benefits are particularly important in the treatment of conditions that require high-dose or chronic administration of botulinum toxin. Additionally, the decreased in LD50 Unit doses of inventive formulations allows for controlled administration limits diffusion. The present invention also provides methods of treating neuromuscular diseases and pain, using low-dose botulinum toxin.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.